The impact of workload changes and staff availability on IV chemotherapy services
- 1 December 2003
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 9 (4) , 123-128
- https://doi.org/10.1191/1078155203jp112oa
Abstract
Objectives. To determine the extent of change in intravenous (IV) chemotherapy workload in recent years, the availability of specialist pharmacy and nursing staff to carry out this work and the service implications of any mismatch between these two parameters. To determine the volume of chemotherapy currently administered for metastatic colorectal cancer (MCRC) to allow assessment of the possible workload implication of a switch to oral fluoropyrimidine therapy. Design. An anonymous postal survey of pharmacist members of the British Oncology Pharmacy Association (BOPA) and their nursing colleagues. Response. 0f 104 questionnaires distributed, 54 were returned (response rate 51.9%). Data summary. Ninety-three per cent of pharmacists reported an increase averaging 178% (range 15]/500%) in the volume of IV chemotherapy being prepared by their units over the last five years, with the average unit currently producing 896 (range 110]/5000) doses each month. Pharmacist and nurse recruitment difficulties were also reported almost universally. The combination of these two factors led to reported problems for both staff and patients, with a majority of nursing and pharmacy staff noting increased staff stress and prolonged patient waiting times. A significant minority of departments have already taken, generally undesirable, steps to address a significant imbalance between chemotherapy workload and service capacity, including restricting clinical trial activity and other aseptic dispensing work. Conclusions. Rapid expansion in the use of IV cytototoxic chemotherapy has resulted in pharmacy and nursing services facing severe pressure. Imaginative solutions are necessary if safe and efficient services are to be maintained. These may include increased use of oral fluorpyrimidines for the first-line treatment of MCRC, which this survey indicates accounts for about 10% of IV chemotherapy administered in the UK.Keywords
This publication has 10 references indexed in Scilit:
- Choice of Chemotherapy Regimen for Advanced Colorectal CancerClinical Oncology, 2002
- Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?British Journal of Cancer, 2002
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Capecitabine as first-line treatment in colorectal cancerEuropean Journal Of Cancer, 2002
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal Of Cancer, 2002
- Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapyAmerican Journal of Health-System Pharmacy, 2001
- Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinomaEuropean Journal Of Cancer, 2001
- Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?Journal of Clinical Oncology, 1998
- Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science TrustJournal of Oncology Pharmacy Practice, 1998
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997